LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery

This study is looking for adults aged 18 or older who are scheduled for certain types of planned (not emergency) heart surgery involving a heart-lung machine. This includes operations like coronary bypass surgery or valve replacements.

To join, you also need to have some risk factors that make it more likely for your kidneys to be affected by surgery. This might be if you have some existing kidney problems (even mild ones), are over 75, are having a combination of valve and coronary surgery, have a certain heart condition (weakened pumping ability), or have conditions like diabetes, high blood pressure, or high cholesterol.

Women who could become pregnant must be using effective birth control during the study. Pregnant or breastfeeding women cannot take part.

If you decide to take part, you'll first have some screening checks up to two weeks before your surgery to make sure you're a good fit for the study. If you qualify, you'll be randomly assigned to receive either the LSALT peptide or a placebo (a dummy treatment that looks the same but has no active drug). You won't know which one you're getting, and neither will your doctors – this is called 'double-blind'.

The study medicine will be given through a drip for about an hour, twice a day for five days, starting at least one hour before your surgery begins. Throughout this time, and for a few weeks after, the study team will regularly check your physical health, vital signs (like blood pressure), and monitor your urine output. They will also take blood samples daily to check your kidney function and other health markers. You'll continue to receive all the standard care your hospital would normally provide. Your safety and kidney function will be followed up until about 28 days after your surgery.